Letters
NICE and thromboembolism
Lifeblood responds to criticisms in Welfare’s personal view article
BMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e403 (Published 17 January 2012) Cite this as: BMJ 2012;344:e403
- Annya Stephens-Boal, executive officer1,
- Shelley Webster, chair1,
- Kim Carter, trustee1,
- Ian M Franklin, trustee1,
- Brian Gardner, trustee1,
- Simon Hart, trustee1,
- Beverley J Hunt, trustee1,
- Simon Noble, trustee1,
- Robin Offord, trustee1
- 1Lifeblood: The Thrombosis Charity, PO Box 58, Llanwrda SA19 0AD, UK
- lifeblood.charity{at}gmail.com
Any belief that the charity Lifeblood is controlled by big pharma is a misconception.1 Lifeblood has always striven to be independent; around 58% of our income is from public donations. All funding from drug companies is ring fenced for educational or awareness projects.
In 2008 an article suggested that Lifeblood endorsed a new oral anticoagulant without Lifeblood’s knowledge and consent. Lifeblood reported Boehringer Ingelheim for breaching the …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.